Introduction
============

Multiple myeloma is a B cell malignancy characterized by osteolytic bone destruction resulting from asynchronous bone turnover, that is, the increased osteoclastic resorption of bone is not accompanied by increased bone formation ([@b6-tcrm-4-1371]; [@b2-tcrm-4-1371]). Bone disease can lead to bone pain, diffuse osteopenia, focal lytic lesions, pathologic fractures, spinal cord compression, and hypercalcemia, and is a major cause of morbidity and mortality in patients with myeloma ([@b20-tcrm-4-1371]).

Bisphosphonates, in the form of pamidronate and zoledronic acid, which have been validated as adjunctive therapy in the prevention and treatment of myeloma bone disease, inhibit osteoclastic activity and are effective in the treatment of cancer associated hypercalcemia ([@b1-tcrm-4-1371]). The second-generation bisphosphonate, pamidronate (pamidronate disodium), is a potent inhibitor of bone absorption at doses that do not affect bone mineralization, and is now a mainstay of myeloma therapy ([@b7-tcrm-4-1371]; [@b1-tcrm-4-1371]). The most effective dose for normalizing serum calcium concentrations in a dose-ranging trial in patients with cancer-associated hypercalcemia was found to be 90 mg of pamidronate ([@b16-tcrm-4-1371]). For multiple myeloma patients with bone disease and no pre-existing renal impairment, newly updated guidelines ([@b9-tcrm-4-1371]; [@b8-tcrm-4-1371]) recommend an intravenous pamidronate 90 mg infusion delivered over at least 2 hours or zoledronic acid 4 mg delivered over 50 minutes every 3 to 4 weeks for 2 years. Reducing the initial pamidronate dose is recommended for patients with pre-existing renal insufficiency.

Intravenous bisphosphonates are eliminated almost exclusively by the kidneys; this elimination is dependent on the patient's creatinine clearance ([@b14-tcrm-4-1371]). Pamidronate-induced renal deterioration depends on dose, and infusion time. It usually occurs with doses over 180 mg ([@b12-tcrm-4-1371]; [@b4-tcrm-4-1371]; [@b13-tcrm-4-1371]) rather than infusion time of less than 2 hours ([@b10-tcrm-4-1371]; [@b5-tcrm-4-1371]; [@b11-tcrm-4-1371]). In a large trial, comprising more than 1600 patients, the incidence of renal toxicity was 9.3% for pamidronate and 10.7% for zoledronic acid ([@b17-tcrm-4-1371]). In this clinical trial, renal deterioration occurred in 6.7%--10% of patients treated with a 2-hour infusion of pamidronate, depending on the renal toxicity definition.

Known pamidronate complications are fever/pyrexia, nausea, emesis, fatigue, headache, hypocalcemia, hypophosphatemia, hypomagnesemia, lymphocytopenia, thrombocytopenia, rigidity, arthralgia, and myalgia. In addition, local injection site skin reactions including pain, redness, swelling, indurations, phlebitis, and thrombophlebitis are described. Serious complications, occurring in less than 2% of patients, include acute systemic inflammatory reaction, ocular inflammation, renal failure, nephritic syndrome, electrolyte imbalance, and osteonecrosis of the maxilla and mandible ([@b15-tcrm-4-1371]; [@b18-tcrm-4-1371]).

Some recently published articles suggest that the risk of renal deterioration may not increase significantly when pamidronate is infused over 1 hour ([@b19-tcrm-4-1371]). The results of the 1-hour comparator trial including 80 multiple myeloma patients conducted by [@b3-tcrm-4-1371] suggest that the prevalence of renal deterioration was not significantly different in patients treated with a 2-hour infusion. Reducing pamidronate administration time would also help to reduce the average cost per treatment, and the waiting list, and benefit quality of life for the patient.

Based on early data on the safety of shorter pamidronate infusion time, patients with multiple myeloma at the out-patient clinic in Uddevalla were given 1-hour infusions from year 2003.

Method
======

Study design
------------

This retrospective study, from 2003 to April 2007, included all patients treated with pamidronate, who had multiple myeloma and no pre-existing renal impairment. The study was performed in the Hematology Section of Uddevalla Hospital, Sweden. S-creatinine (S-Cr), S-calcium (S-Ca) or S-free ionized calcium, and S-albumin before and during the pamidronate treatment were recorded.

Assessments
-----------

Renal deterioration during the treatment was defined as S-Cr increase ≥44.2 μmol/L or as an increase ≥2 times the baseline if baseline S-Cr was ≥124 μmol/L. For those patients with baseline S-Cr ≥124 μmol/L, renal deterioration during the treatment was defined as S-Cr increase ≥88.4 μmol/L, or as an increase ≥2 times the baseline. Our laboratory has as total S-Ca reference value the range 2.32--2.62 (mmol/L). Baseline S-Cr or S-Ca was defined as the value reported closest to the time of the first pamidronate dose within the 3 months before that dose. We assessed the increase of S-Cr and S-Ca after each treatment, and for each patient.

Statistical analysis
--------------------

Standard statistical methods were employed. Mean values and standard deviation (±SD) are reported. The difference between means was tested with Student's t test and the non parametric Mann-Whitney test when needed. Differences between the results in our study and comparable trials were tested with Fisher's exact test and chi square test. The difference between means was considered statistically significant if p \< 0.05.

Results
=======

We identified 79 patients who had undergone pamidronate 90 mg therapy, and who had no pre-existing renal impairment. Their mean age was 68 years and 63% of patients were men. The mean number of pamidronate cycles per patient was 10.7. The number of infusions with evaluable data concerning S-Cr, adverse effects such as S-Ca, or S-free ionized calcium were 793, 846, and 669 respectively. The S-Cr and total S-Ca before treatment, also called the baseline, were 99.8 μmol/L and 2.53 mmol/L respectively. The difference in baseline S-Cr between the sexes was significant ([Table 1](#t1-tcrm-4-1371){ref-type="table"}).

Renal deterioration
-------------------

The prevalence of renal deterioration between 2 pamidronate infusions was 2.2% for the total population and 0.8% for women (not statistically significant difference). S-Cr increase at least between 2 pamidronate infusions was observed in 8.9% of the patients. The distribution of renal impairment between the sexes was similar; 5 men and 2 women ([Table 2](#t2-tcrm-4-1371){ref-type="table"}).

Analyzing the cause of creatinine increase in those 7 patients revealed that in 3 patients the increase was a result of progress of the disease, and that in 2, it resulted from opportunistic infections. In the remaining 2 patients no obvious cause could be found, and the interpretation was that pamidronate-induced renal impairment was probable. These two patients received 10 and 26 infusions, respectively.

Adverse effects
---------------

The infusions of pamidronate were tolerated well. No fatal or life-threatening events occurred. Previously described adverse effects of pamidronate excluded osteonecrosis of the jaw, but included other events related to infusion (hypertension), observed in 0.8% of infusions or 7.6% of patients. One male patient was diagnosed with osteonecrosis of the jaw after less than 10 pamidronate cycles ([Table 2](#t2-tcrm-4-1371){ref-type="table"}).

Hypocalcemia
------------

During therapy, the minimum values recorded of S-Ca and S-free ionized calcium were 2.09 and 1.13 mmol/L, respectively. The mean total S-Ca was 0.05 mmol/L, lower than the baseline total S-Ca ([Table 2](#t2-tcrm-4-1371){ref-type="table"}).

Pamidronate therapy failure
---------------------------

The incidence of this newly introduced term for pamidronate therapy, demonstrated as persistent hypercalcemia after two consecutive infusions, was 1.3%. This value reduced to 0.9% when patients with progression of multiple myeloma disease were excluded.

Discussion
==========

The 1-hour 90 mg pamidronate infusion for patients with multiple myeloma, and no pre-existing renal impairment, was shown to be safe from the risk of nephrotoxicity and pamidronate induced hypocalcemia, and was well tolerated, in accordance with the present pamidronate therapy guidelines ([@b9-tcrm-4-1371]; [@b8-tcrm-4-1371]). Renal deterioration occurred in 8.9% of the 79 patients. The proportion of the events related to infusion, including wzzell-known infusion-related adverse effects, was approximately 10% and the incidence of therapy failure was 1.3%. The comparator study conducted by [@b3-tcrm-4-1371] showed that renal deterioration occurred in 15% of patients, and that the median increase in S-Cr was 13%. The difference in renal deterioration between our and the comparator study is not significant (p = 0.343).

Pamidronate's efficacy is also demonstrated in our trial by the low incidence of pamidronate therapy failure, defined as persistent tumor-induced hypercalcemia after two infusions in a row, independent of the progression status of multiple myeloma disease.

During the pamidronate treatment a trend towards a decrease in S-Cr was observed. No patients showed any clinical symptoms related to hypocalcemia. Comparison of the baseline mean, and mean during treatment, of S-Cr for each patient in our study population showed no significant reduction in S-Cr. However, further clinical trials are needed to fully investigate this observation. We assume that the low incidence of nephrotoxicity in our study population is due to the careful choice of patients for the decreased pamidronate infusion, based on previous studies, our clinical experience, and recommendations concerning the indications, dose-optimization, and duration of pamidronate therapy.

Because males are slightly more commonly affected by multiple myeloma, they normally represent a larger group in a study population. The other factor that contributed to fewer females in the study was our intention to treat with a lower dose individuals with low weight, based on our clinical experience. The careful selection of female individuals rather than the fewer pamidronate cycles at 8.8 compared to 11.8 (statistically insignificant difference) in men is thought to have contributed to the differences in prevalence of renal deterioration such as in the percentage of the reduction of S-Cr between the two sexes. Renal impairment developed in 6.9% of women and 10% of men, but a reduction of more than 30% of baseline S-Cr occurred in 3.5% of women and 8% of men.

In conclusion, monthly infusions of pamidronate are an effective adjunctive treatment to palliate the destructive skeletal events often occuring in patients with multiple myeloma. One hour's treatment with 90 mg of pamidronate in patients with no pre-existing renal impairment is proved to be safe and well tolerated, and to improve patient comfort and well-being. Our retrospective trial showed that reducing the infusion time from 4 hours to 1 hour caused no significant increase in nephrotoxicity, hypocalcemia, and adverse effects.

The study was partially economically supported by FoU-rådet Fyrbodal, Sweden and an abstract has been presented at the Swedish National Medicine Conference 2007 in Stockholm.
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###### 

Patient demographics, number of pamidronate cycles per patient, and baseline creatinine and calcium concentrations (mean ± SD, range within parenthesis)

                                      Total                      Female                                                           Male
  ----------------------------------- -------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------
  No of pat. identified               79                         29 (37%)                                                         50 (63%)
  Mean age at diagnosis (years)       68 ± 10.4 (38--88)         70 ± 8.7 (53--86)                                                67 ± 11.1 (38--88)
  No. of pamidronate cycles/no pat.   10.7 ± 7.1 (1--31)         8.8 ± 5.8 (1--25)                                                11.8 ± 7.6 (1--31)
  S-Cr (μmol/L)                       99.8 ± 37.8 (52--267)      87 ± 23.7[a](#tfn1-tcrm-4-1371){ref-type="table-fn"} (52--160)   107.5 ± 42.7[a](#tfn1-tcrm-4-1371){ref-type="table-fn"}(54--267)
  Total S-Ca (mmol/L)                 2.53 ± 0.19 (2.24--3.02)   2.51 ± 0.14 (2.24--2.94)                                         2.54 ± 0.21 (2.24--3.02)

The difference in baseline S-Cr between the two sexes is significant (p \< 0.03).

**Abbreviations:** S-Cr, serum creatinine; S-Ca, serum calcium.

###### 

Events of serum creatinine increase, infusion related events (inclusive adverse, exclusive osteonecrosis of the jaw), hypocalcemia (\<2.32 mmol/L) such as S-Cr and S-Ca range under treatment in 79 patients with multiple myeloma given one hour pamidronate 90 mg infusion. For each parameter, the number of infusions with evaluable data are used

                                                Total          Female       Male
  --------------------------------------------- -------------- ------------ --------------
  S-Cr increasing events/no infusions           17/790 2.2%    2/245 0.8%   15/545 2.8%
  S-Cr increasing events/no patients            7/79 8.9%      2/29 6.9%    5/50 10%
  S-Cr range during treatment (μmol/L)          37--333        37--175      44--333
  Events related to the infusion/no infusions   7/846 0.8%     2/256 0.8%   5/590 0.9%
  Events related to the infusion/no patients    6/79 7.6%      2/29 6.9%    4/50 8%
  Hypocalcemia events/no infusions              69/669 10.3%   8/209 3.8%   61/460 13.3%
  Hypocalcemia events/no patients               28/79 35.4%    6/29 20.7%   22/50 44%
  S-Ca range during treatment (mmol/L)          2.09--3.94     2.18--3.94   2.09--3.28

**Abbreviations:** S-Cr, serum creatinine; S-Ca, serum calcium.
